skip to main content
US FlagAn official website of the United States government
dot gov icon
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
https lock icon
Secure .gov websites use HTTPS
A lock ( lock ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.


Search for: All records

Creators/Authors contains: "Gablenz, Paula"

Note: When clicking on a Digital Object Identifier (DOI) number, you will be taken to an external site maintained by the publisher. Some full text articles may not yet be available without a charge during the embargo (administrative interval).
What is a DOI Number?

Some links on this page may take you to non-federal websites. Their policies may differ from this site.

  1. Abstract We consider problems where many, somewhat redundant, hypotheses are tested and we are interested in reporting the most precise rejections, with false discovery rate (FDR) control. This is the case, for example, when researchers are interested both in individual hypotheses as well as group hypotheses corresponding to intersections of sets of the original hypotheses, at several resolution levels. A concrete application is in genome-wide association studies, where, depending on the signal strengths, it might be possible to resolve the influence of individual genetic variants on a phenotype with greater or lower precision. To adapt to the unknown signal strength, analyses are conducted at multiple resolutions and researchers are most interested in the more precise discoveries. Assuring FDR control on the reported findings with these adaptive searches is, however, often impossible. To design a multiple comparison procedure that allows for an adaptive choice of resolution with FDR control, we leverage e-values and linear programming. We adapt this approach to problems where knockoffs and group knockoffs have been successfully applied to test conditional independence hypotheses. We demonstrate its efficacy by analysing data from the UK Biobank. 
    more » « less